A First|in|Human Phase 1 Study of Abbv|319

A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug ...

This phase 1 study evaluates safety and clinical activity of ABBV-319 monotherapy in patients with relapsed or refractory (R/R) B-cell malignancies.

A Phase 1 Study of ABBV-319 in People With B-Cell Cancers

Full Title Study M22-716: A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy ...

ABBV-319: a CD19-targeting glucocorticoid receptor modulator ...

Collectively, these data support the ongoing evaluation of ABBV-319 in a phase 1 clinical trial. ... To our knowledge, this is the first study ...

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation ...

Purpose. ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase ...

First-in-Human Phase I Study of ABBV-838, an Antibody ... - PubMed

ABBV-838 is an antibody-drug conjugate targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells.

A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug ...

CLIN is intended for personal, non-commercial use only. By accessing this site without logging in, you agree not to use any content, data, or resources for ...

A Phase I First-in-Human Study of ABBV-011, a Seizure-Related ...

ABBV-011 1.0 mg/kg every 3 weeks monotherapy was well tolerated and demonstrated encouraging antitumor activity in heavily pretreated patients with ...

A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug ...

A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug Conjugate Composed of a CD19 Antibody Linked to a Potent Proprietary Glucocorticoid Receptor ...

First-in-Human Phase I Study of ABBV-085, an Antibody–Drug ...

ABBV-085 is a monomethyl auristatin-E antibody–drug conjugate that targets LRRC15 and showed antineoplastic efficacy in preclinical experiments. Herein, we ...

AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with ...

Data from the dose-escalation and colorectal cancer (CRC) dose-expansion cohort of an ongoing first-in-human Phase 1 study (NCT05029882) of ABBV ...

A First In Human Multicenter, Open-Label Study to Determine the ...

ABBV-319 is an investigational drug being developed for the treatment of R/R DLBCL, R/R FL, or R/R CLL. This study will include a dose escalation phase to ...

770 Safety, efficacy, and pharmacokinetic results from a phase I first ...

Herein, we report preliminary safety, efficacy, and pharmacokinetic (PK) results from a first-in-human, phase 1 study (NCT03821935) assessing ABBV-151 ± ...

MA09.09 First-In-Human Phase 1 Study of ABBV-399, an Antibody ...

ABBV-399 is a first-in-class ADC composed of ABT-700, an anti–c-Met antibody, conjugated to monomethyl auristatin E (a microtubule inhibitor). Preclinical data ...

Clinical Trials Using Anti-SEZ6 Antibody-drug Conjugate ABBV-706

You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you. Trials -24-0 of 1.

MO4-2 Phase 1 study of ABBV-400, a novel anti-Met antibody drug ...

The first-generation c-Met targeting antibody-drug conjugate carrying a monomethyl auristatin E payload, telisotuzumab vedotin (ABBV-399), recently received ...

AbbVie Showcases Advancement of Solid Tumor Pipeline at ESMO ...

New safety and efficacy data from a Phase 1 study (NCT05029882) of ABBV ... Dose escalation results from a first-in-human study of ABBV-400, a ...

A Phase 1 First-in-Human Study Evaluating Safety ... - UroToday

Study Type: Interventional. Clinical Trials Identifier NCT 8-digits: NCT06318273. Sponsor: AbbVie. Phase: Phase 1. Eligibility: Age: minimum 18 ...

Abstract ND01: ABBV-319: A first-in-class Glucocorticoid Receptor ...

A first in-human Phase 1 clinical trial evaluating ABBV-319 in B-cell malignancies (DLBCL, FL, CLL) was recently initiated in late 2022 ...

A Phase 1 First-in-Human Study Evaluating Safety ...

ABBV-969 is an investigational drug being developed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). There are ...

A Phase 1 Study with ABBV-CLS-484 Alone and in Combination in ...

No known active disease present within ≥ 3 years before first dose of study treatment and felt to be at low recurrence by investigator. - Adequately ...